GAIN THERAPEUTICS, INC Retained Earnings
GAIN THERAPEUTICS, INC (GANX) had Retained Earnings of -$111.64 million as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2026-08-11
- 2026-06-30: Retained Earnings (Accumulated Deficit) -$111.64M.
- 2026-03-31: Retained Earnings (Accumulated Deficit) -$101.36M.
- 2025-12-31: Retained Earnings (Accumulated Deficit) -$101.36M; Retained Earnings (Accumulated Deficit) as first filed -$81.19M.
- 2025-09-30: Retained Earnings (Accumulated Deficit) -$81.19M.
| Period end | Retained Earnings (Accumulated Deficit) | Retained Earnings (Accumulated Deficit) as first filed |
|---|---|---|
| 2026-06-30 | -$111.64M 10-Q · filed 2026-08-11 | |
| 2026-03-31 | -$101.36M 10-Q · filed 2026-05-11 | |
| 2025-12-31 | -$101.36M 10-Q · filed 2026-08-11 | -$81.19M 10-K · filed 2026-03-26 |
| 2025-09-30 | -$81.19M 10-Q · filed 2025-11-12 | |
| 2025-06-30 | -$81.19M 10-Q · filed 2025-08-12 | |
| 2025-03-31 | -$81.19M 10-Q · filed 2025-05-14 | |
| 2024-12-31 | -$60.78M 10-K · filed 2026-03-26 | |
| 2024-09-30 | -$60.78M 10-Q · filed 2024-11-14 | |
| 2024-06-30 | -$60.78M 10-Q · filed 2024-08-08 | |
| 2024-03-31 | -$60.78M 10-Q · filed 2024-05-14 | |
| 2023-12-31 | -$38.52M 10-K · filed 2025-03-27 | |
| 2023-03-31 | -$38.52M 10-Q · filed 2023-05-12 | |
| 2022-12-31 | -$20.93M 10-K · filed 2024-03-26 | |
| 2022-09-30 | -$20.93M 10-Q · filed 2022-11-10 | |
| 2022-06-30 | -$20.93M 10-Q · filed 2022-08-08 | |
| 2022-03-31 | -$20.93M 10-Q · filed 2022-05-16 | |
| 2021-12-31 | -$7.03M 10-K · filed 2023-03-23 | |
| 2021-09-30 | -$7.03M 10-Q · filed 2021-11-12 | |
| 2021-06-30 | -$7.03M 10-Q · filed 2021-08-12 | |
| 2021-03-31 | -$7.03M 10-Q · filed 2021-05-10 | |
| 2020-12-31 | -$3.46M 10-K · filed 2022-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Telomir Pharmaceuticals, Inc. (TELO) | United States | $0.084B | |
| Lexaria Bioscience Corp. (LEXX) | $0.084B | -1.92 | |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B |